M&A Deal Summary

Valneva Acquires Iomai

On August 5, 2008, Valneva acquired medical products company Iomai from EW Healthcare Partners for 75M EUR

Acquisition Highlights
  • This is Valneva’s 1st transaction in the Medical Products sector.
  • This is Valneva’s 0th largest (disclosed) transaction.
  • This is Valneva’s 1st transaction in the United States.
  • This is Valneva’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2008-08-05
Target Iomai
Sector Medical Products
Buyer(s) Valneva
Sellers(s) EW Healthcare Partners
Deal Type Add-on Acquisition
Deal Value 75M EUR

Target

Iomai

Gaithersburg, Pennsylvania, United States
website
Developed a method to safely and more effectively deliver vaccines through the use of a skin patch and without injections.

Search 192,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Valneva

Saint-Herblain, France

website

Category Company
Sector Life Science
Employees254
Revenue 348M EUR (2021)
DESCRIPTION

Valneva is a biotechnology company which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Valneva is based in Saint-Herblain, France.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2008) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-28 Vivalis SA

Nantes, France

Vivalis is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs.

Buy -

Seller(S) 1

SELLER

EW Healthcare Partners

Investor Investor Investor Investor Investor

website

Category Growth Capital Firm
Founded 1985
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.

DEAL STATS #
Overall 13 of 52
Sector (Medical Products) 6 of 23
Type (Add-on Acquisition) 7 of 34
State (Pennsylvania) 2 of 7
Country (United States) 12 of 45
Year (2008) 4 of 5
Size (of disclosed) 19 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-06-16 LipoSonix

California, United States

LipoSonix is developing technology for noninvasive cosmetic surgery applications. LipoSonix was acquired by Medicis Pharmaceutical.

Sell $150M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-12-10 Dow Pharmaceutical Sciences

Petaluma, California, United States

Developer, manufacturer and marketer as well as formulator of topical therapies focused on the dermatology market.

Sell $285M
Mergr

Product

Company

Legal